Clinical Trials — Страница 409

Hospital admissions among patients with Comorbid Substance Use disorders: a secondary analysis of predictors from the NavSTAR Trial

28 апреля, 2024

Addict Sci Clin Pract. 2024 Apr 28;19(1):33. doi: 10.1186/s13722-024-00463-9. ABSTRACT BACKGROUND: Individuals with substance use disorders (SUDs) frequently use acute hospital services. The Navigation Services to Avoid Rehospitalization (NavSTAR) trial found that a patient navigation intervention for hospitalized patients with comorbid SUDs reduced subsequent inpatient admissions compared to treatment-as-usual (TAU). METHODS: This secondary analysis extends…
Read more →
Blood Interleukin-18 (IL-18) and IL-18 Binding Protein (IL-18BP) Levels Following Midline Laparotomy: A Prospective Randomized Study of Patients With Benign Disease and Patients With Cancer

28 апреля, 2024

Anticancer Res. 2024 May;44(5):2039-2046. doi: 10.21873/anticanres.17007. ABSTRACT BACKGROUND/AIM: The acute phase immune response (APR) in midline laparotomy (MLa) patients following surgery has been rarely studied, with no studies assessing the association of blood IL-18 (interleukin-18) and IL-18BP (IL-18 binding protein) values with the numeric rating scale (NRS) pain score following MLa. PATIENTS AND METHODS: Blood…
Read more →
Potential Prodromal Digital Postural Sway Markers for Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) Detected via Dual-Tasking and Sensory Manipulation

27 апреля, 2024

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase

Emily C Timm April 27, 2024 Sensors (Basel). 2024 Apr 18;24(8):2586. doi: 10.3390/s24082586. ABSTRACT FXTAS is a neurodegenerative disorder occurring in some Fragile X Messenger Ribonucleoprotein 1 (FMR1) gene premutation carriers (PMCs) and is characterized by cerebellar ataxia, tremor, and cognitive deficits that negatively impact balance and gait and increase fall risk. Dual-tasking (DT) cognitive-motor…
Read more →
An Era of Digital Healthcare-A Comprehensive Review of Sensor Technologies and Telehealth Advancements in Chronic Heart Failure Management

27 апреля, 2024

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase

Tejaswini Manavi April 27, 2024 Sensors (Basel). 2024 Apr 16;24(8):2546. doi: 10.3390/s24082546. ABSTRACT Heart failure (HF) is a multi-faceted, complex clinical syndrome characterized by significant morbidity, high mortality rate, reduced quality of life, and rapidly increasing healthcare costs. A larger proportion of these costs comprise both ambulatory and emergency department visits, as well as hospital…
Read more →
A Phosphenotron Device for Sensoric Spatial Resolution of Phosphenes within the Visual Field Using Non-Invasive Transcranial Alternating Current Stimulation

27 апреля, 2024

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase

Faraz Sadrzadeh-Afsharazar April 27, 2024 Sensors (Basel). 2024 Apr 14;24(8):2512. doi: 10.3390/s24082512. ABSTRACT This study presents phosphenotron, a device for enhancing the sensory spatial resolution of phosphenes in the visual field (VF). The phosphenotron employs a non-invasive transcranial alternating current stimulation (NITACS) to modulate brain activity by applying weak electrical currents to the scalp or…
Read more →
Human Herpes Virus-6 (HHV-6) Reactivation after Hematopoietic Cell Transplant and Chimeric Antigen Receptor (CAR)- T Cell Therapy: A Shifting Landscape

27 апреля, 2024

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase

Eleftheria Kampouri April 27, 2024 Viruses. 2024 Mar 24;16(4):498. doi: 10.3390/v16040498. ABSTRACT HHV-6B reactivation affects approximately half of all allogeneic hematopoietic cell transplant (HCT) recipients. HHV-6B is the most frequent infectious cause of encephalitis following HCT and is associated with pleiotropic manifestations in this setting, including graft-versus-host disease, myelosuppression, pneumonitis, and CMV reactivation, although the…
Read more →
Case Report: Long-Term Survival of a Patient with Cerebral Metastasized Ovarian Carcinoma Treated with a Personalized Peptide Vaccine and Anti-PD-1 Therapy

27 апреля, 2024

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase

Henning Zelba April 27, 2024 Vaccines (Basel). 2024 Apr 9;12(4):397. doi: 10.3390/vaccines12040397. ABSTRACT Ovarian cancer is one of the most common cancers among women and the most lethal malignancy of all gynecological cancers. Surgery is promising in the early stages; however, most patients are first diagnosed in the advanced stages, where treatment options are limited.…
Read more →
Evaluation of a FlpA Glycoconjugate Vaccine with Ten N-Heptasaccharide Glycan Moieties to reduce Campylobacter jejuni Colonisation in Chickens

27 апреля, 2024

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase

Ricardo Corona-Torres April 27, 2024 Vaccines (Basel). 2024 Apr 9;12(4):395. doi: 10.3390/vaccines12040395. ABSTRACT Campylobacter is a major cause of acute gastroenteritis in humans, and infections can be followed by inflammatory neuropathies and other sequelae. Handling or consumption of poultry meat is the primary risk factor for human campylobacteriosis, and C. jejuni remains highly prevalent in…
Read more →
Advancing Postoperative Pain Management in Oral Cancer Patients: A Systematic Review

27 апреля, 2024

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase

Angelo Michele Inchingolo April 27, 2024 Pharmaceuticals (Basel). 2024 Apr 22;17(4):542. doi: 10.3390/ph17040542. ABSTRACT The goal of this review is to shed light on the management of orofacial discomfort after a cancer diagnosis in the head and neck region. A search was conducted on PubMed, Scopus, and Web of Science to identify studies on postoperative…
Read more →
Budesonide Attains Its Wide Clinical Profile by Alternative Kinetics

27 апреля, 2024

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase

Ralph Brattsand April 27, 2024 Pharmaceuticals (Basel). 2024 Apr 15;17(4):503. doi: 10.3390/ph17040503. ABSTRACT The introduction of inhaled corticosteroids (ICSs) changed over a few decades the treatment focus of mild-to-moderate asthma from bronchodilation to reduction in inflammation. This was achieved by inhaling a suitable corticosteroid (CS), giving a high, protracted airway concentration at a low total…
Read more →